Liora Monofilament Scaffold
TELA Bio, Inc. · Decision date Sep 28, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 28, 2026 for K260474, the Liora Monofilament Scaffold submitted by TELA Bio, Inc. of Malvern, Pennsylvania. The device is a sterile, resorbable monofilament scaffold made of 100% poly(lactic co-glycolic acid), classified as surgical mesh under 21 CFR 878.3300, Class II, product code FTL, in the General and Plastic Surgery specialty. Clearance is not premarket approval.
The 510(k) summary compares Liora with primary predicate Polydioxanone Surgical Scaffold (K181094) and reference devices OviTex PRS Long-Term Resorbable (K243595) and TIGR Matrix (K191749). The summary states the same intended use as the predicate, with added specification for muscle flap transfer as temporary support, and identifies differences in materials of construction, thickness, areal density and pore size. The summary asserts these differences raise no different questions of safety or effectiveness; independent clinical outcome data are not provided in the source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260474
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- TELA Bio, Inc.
- Product code
- FTL
- Decision code
- SESE
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mesh, Surgical, Polymeric.
- Applicant
- TELA Bio, Inc.
- Product code
- FTL
- FDA device class
- 2
FDA decision timeline
K260474 received
Application receipt date recorded by FDA.
K260474 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
TELA Bio, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Malvern, PA
Sources and methodology
- Original FDA record: K260474
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records